NCT06863467View on ClinicalTrials.gov

Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 20, 2025

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Renal Insufficiency, ChronicChronic Kidney Disease stage3Chronic Kidney Disease stage4
Interventions
DRUG

Intravenous Gemini

Single ascending intravenous dose infused once over 10-15 minutes.

DRUG

Intravenous placebo

Intravenous sugar solution infused in a single dose over 10-15 minutes.

Trial Locations (3)

78212

RECRUITING

Clinical Advance Center, PLLC, San Antonio

91911

RECRUITING

California Institute of Renal Research, Chula Vista

92942

RECRUITING

California Institute of Renal Research, La Mesa

All Listed Sponsors
lead

Revelation Biosciences, Inc

INDUSTRY